Location History:
- Aarhus C, DK (1999)
- DK-5260 Odense S, DK (2003 - 2009)
- Odense, DK (2006 - 2010)
- Odense S, DK (2007 - 2014)
Company Filing History:
3 out of 3 
1 out of 93 
1 out of 3 Years Active: 1999-2014
Title: The Innovative Contributions of Peter Mose Larsen
Introduction
Peter Mose Larsen, residing in Odense S, Denmark, is a prolific inventor with a remarkable portfolio that includes ten patents. His work is primarily focused on improving health outcomes through innovative biomedical solutions. His contributions to the field of diabetes treatment exemplify his commitment to advancing medical science.
Latest Patents
One of Peter's notable patents is centered around an anti-diabetic extract derived from rooibos. This invention presents novel compositions designed to treat Type 2 diabetes. The innovation introduces a new application for aspalathin and rutin, showcasing their potential in preventing and treating diabetes. The invention also encompasses methods for decreasing blood glucose levels and offers food and beverage formulations that incorporate these anti-diabetic agents, thereby contributing significantly to diabetes management.
Another significant patent relates to biochemical markers of the human endometrium. This invention involves the assay of endometrial secreted polypeptides in body fluids, aimed at detecting specific polypeptides correlated with endometrial status. This advancement carries implications for diagnosing conditions such as hyperplasia or adenocarcinoma, enhancing early detection and treatment strategies.
Career Highlights
Throughout his career, Peter Mose Larsen has made notable strides in biotechnology and medical research. His work has positioned him as a leader in developing innovative approaches to diabetes treatment and women's health diagnostics. His expertise and creativity have resulted in a series of patents that reflect his dedication to improving patient outcomes through scientific innovation.
Collaborations
Peter has worked alongside esteemed colleagues, including Stephen J. Fey and Allan E. Karlsen. Their collaborations have fostered a dynamic exchange of ideas and expertise, further enhancing the depth and impact of their research. Additionally, he has affiliated with notable companies such as Pride Proteomics A/S, contributing to advancements in biotechnological applications.
Conclusion
In conclusion, Peter Mose Larsen is a distinguished inventor whose work has significantly impacted the medical and biotechnological fields. His innovations in diabetes treatment and diagnostic markers not only exemplify his inventive spirit but also his commitment to enhancing health outcomes. With a continuous focus on development and research, Peter's contributions will undoubtedly pave the way for future advancements in the industry.